Engineered IL-10 variants elicit potent immuno-modulatory activities at therapeutic low ligand doses
C. Gorby, J. Sotolongo Bellon, S. Wilmes, W. Warda, E. Pohler, P. Fyfe, A. Cozzani, C. FERRAND, M. Walter, S. MITRA, J. Piehler, I. Moraga
This study engineered IL-10 variants with enhanced receptor affinity, showing improved bioactivity and gene expression at lower doses in human monocytes and CD8 T cells.
bioRxiv · Mar 10, 2020Immunology